FOLH1 and pachyonychia congenita: The prospective, randomized multicenter study called “proPSMA” showed that in patients with biopsy-proven high-risk PC, PET/CT with prostate-specific membrane antigen (PSMA PET/CT) imaging is superior to conventional combined CT and bone scintigraphy for primary staging of PC metastases [2,3].